{"schema_version":"secwatch.filing_event.v1","accession":"0001339970-25-000007","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.775724+00:00","generated_at":"2026-05-17T17:14:29.481056+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"aTyr completes Phase 3 EFZO-FIT last patient visit; topline data mid-September 2025","bullets":["Last patient visit completed in Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis; topline data expected mid-September 2025.","Cash, equivalents and investments were $83.2M at June 30, 2025; raised ~$30.7M from ATM offering post-quarter.","R&D expenses $15.4M, G&A $4.9M for Q2 2025.","Interim Phase 2 EFZO-CONNECT data in SSc-ILD showed stable/improved mRSS in efzofitimod-treated patients (n=8).","Advanced ATYR0101 to IND candidate for pulmonary fibrosis; IND filing expected H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001339970-25-000007","json":"https://secwatch.observer/filing/0001339970-25-000007.json","markdown":"https://secwatch.observer/filing/0001339970-25-000007.md","text":"https://secwatch.observer/filing/0001339970-25-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000133997025000007/0001339970-25-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000133997025000007/atyr-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:14:29.481056+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}